CULLINAN THERAPEUTICS, INC. Gain (Loss) on Disposition of Assets
CULLINAN THERAPEUTICS, INC. (CGEM) reported Gain (Loss) on Disposition of Assets of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2024-03-14
- CULLINAN THERAPEUTICS, INC. gain (loss) on disposition of assets for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. gain (loss) on disposition of assets for the quarter ending 2022-12-31 was $63.00K.
- CULLINAN THERAPEUTICS, INC. gain (loss) on disposition of assets for the quarter ending 2021-12-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. gain (loss) on disposition of assets for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. gain (loss) on disposition of assets for fiscal 2022 was $77.00K.
- CULLINAN THERAPEUTICS, INC. gain (loss) on disposition of assets for fiscal 2021 was $0.00.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 9 month as first filed | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | ||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | |||
| 2022-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $77.00K 10-K · filed 2024-03-14 | ||
| 2022-09-30 | $14.00K 10-Q · filed 2023-11-08 | -$14.00K 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |